{"entity":{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","aka":[],"tldr":"Mablink Bioscience, from Lyon, invented PSARlink, a water-soluble polysarcosine linker that hides the greasy cell-killing payload so an antibody can carry a higher load of drug molecules and still stay stable in the blood. Eli Lilly bought the company in 2023, before any of its medicines had reached patients.","summary":"Mablink Bioscience was a preclinical Lyon-based biotech whose PSARlink platform uses a hydrophilic polysarcosine linker arm to mask hydrophobic cytotoxic payloads, enabling homogeneous, plasma-stable antibody-drug conjugates with high drug-to-antibody ratios while preserving pharmacokinetics and tolerability; PSARlink ADCs showed an improved therapeutic index in animal models. The company was funded by a 2021 seed round led by Elaia Partners with UI Investissement and Relyens Innovation Santé, and a July 2022 Series A led by Sofinnova Partners and Mérieux Equity Partners. On 18 October 2023 Mablink announced an agreement to be acquired by Eli Lilly, subject to French Ministry of the Economy approval; terms were not disclosed. The company domain now redirects to lilly.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"Acquisition announcement (BioSpace copy)","url":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["mablink.com redirects to lilly.com, recorded as the website. Series A amount (reported elsewhere as EUR 31 million) not stated in the fetched source and omitted. GlobeNewswire original could not be fetched."],"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.lilly.com/","stage":"acquired","investors":["sofinnova-partners"],"funding":[{"round":"Seed","year":2021,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Led by Elaia Partners; amount not stated in the fetched release copy"},{"round":"Series A","year":2022,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"July 2022, led by Sofinnova Partners and Mérieux Equity Partners; amount not stated in the fetched release copy"},{"round":"Acquisition","year":2023,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Agreement announced 18 October 2023; terms not disclosed"}],"acquiredBy":"eli-lilly"},"route":"/companies/mablink-bioscience/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/"}]}}